Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099255 · ClinicalTrials.gov registry record · Phase 2
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
A Phase 2 study of Large-cell Lymphoma, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT00099255: Completed Phase 2 study of Large-cell Lymphoma, sponsored by Seagen.
NCT00099255 is a Phase 2 study of Large-cell Lymphoma that has completed, run by Seagen. The registered enrollment target is 40 participants, below the 88-participant average among 4 other Large-cell Lymphoma trials with a reported enrollment target (55% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099255, a Phase 2 study of Large-cell Lymphoma, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
Conditions Studied
Interventions
- DRUG SGN-30
Study Locations (13)
California
- University of California at Los Angeles - Los Angeles
- Stanford University - Stanford
Illinois
- Northwestern Universtiy - Chicago
- University of Illinois at Chicago - Chicago
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale - New Haven
Maryland
- Johns Hopkins - Baltimore
Minnesota
- University of Minnesota - Minneapolis
New York
- Memorial Sloan-Kettering - New York
Ohio
- Cleveland University - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00099255 record still lists
NCT00099255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 88-participant average among 4 other Large-cell Lymphoma trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Large-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGN-30 is the first listed.
NCT00099255 lists 13 locations in 11 states (California, Illinois, Alabama).
Frequently Asked Questions
What is clinical trial NCT00099255 about?
NCT00099255 is a clinical study titled "Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma". This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
What is the current status of trial NCT00099255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-09. Estimated completion is 2007-02.
What conditions does trial NCT00099255 study?
This clinical trial studies the following conditions: Large-cell Lymphoma.
What interventions are being tested in trial NCT00099255?
The interventions under investigation include: SGN-30 (DRUG).
Who is sponsoring clinical trial NCT00099255?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00099255 being conducted?
This trial has 13 study locations across Alabama, California, Connecticut, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Telehealth-based Symptom Management for Veterans Treated With Selinexor
ACTIVE NOT RECRUITING
-
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia